Mervyn Chan ¤Ñ¨ÏÅ]°­¤é°O
¤Ñ¨Ï©MÅ]°­~¥i¯à¥u¬O¤@½u¤§®t
mervyn
¼ÊºÙ¡G ·ù
©Ê§O¡G ¨k
°ê®a¡G ­»´ä
« June 2026 »
SMTWTFS
123456
78910111213
14151617181920
21222324252627
282930
³Ì·s¤å³¹
Nippon Karate Tenor ...
¤j´¼­Y·M
¬J¥Í·ì¡A¦ó¥Í«G
¯¬¤j®a½Þ¦~§Ö¼Ö
¯¬¦U¦ì±¡¤H¸`§Ö¼Ö
¤å³¹¤ÀÃþ
¥þ³¡ (201)
2003 SARS (1)
Âå¾Ç¥æ¬y (12)
¤À¨É (102)
¤H¥ÍÆ[ (5)
¤jÁp·ù (5)
¤u§@¤é°O (6)
¥»¦a¬y¦æ­µ¼Ö (2)
¦L«×¸q¤u¤§®È (1)
§Úªº¤p»¡³Ð§@ (1)
§Úªº¥Í¬¡ (14)
§Úªº·R±¡Æ[ (1)
§Ú³ß·Rªººq¦± (21)
§Ú´¿ºt¥Xªººq¼@ (5)
ªB¤Í (1)
ªk«ß±`ÃÑ (4)
®a¤H (4)
°·±d¥Í¬¡ (7)
·Å¬Gª¾·s~Revision (1)
¸q¤u (7)
¸t½Ï­µ¼Ö (1)
³X«È¯d¨¥
³Ìªñ¤T­Ó¤ë©|µL¥ô¦ó¯d¨¥
¦n¤Í¦W³æ
©|µL¥ô¦ó¦n¤Í
ºô¯¸³sµ²
©|µL¥ô¦ó³sµ²
¦Û­qÄæ¦ì(¤@)
©|µL¥ô¦ó¤º®e
¯¸¤º·j´M
2006 ¦~ 12 ¤ë 17 ¤é  ¬P´Á¤é   ´¸¤Ñ


¤p¤ß CA-MRSA ¤ÀÃþ: °·±d¥Í¬¡

½ñ¤J¬î©u¡A¦]°®Àê¦ÓÃzµõªº¥Ö½§¡A¹y¦¨¯fµßÂè­ªº·ÅþH¡A³QºÙ¬°¡u¶W¯Å´cµß¡vªºªÀ°Ï©Ê§ÜÃĩʪ÷¶À¸²µå²yµß¡]CA-MRSA¡^¥ç¦³¥i¯à¶X¾÷¸v­h¡A¤µ¦~­Ó®×¤w¸û¥h¦~¥þ¦~¼W¥[¹O­¿¡C½Ã¥Í¨¾Å@¤¤¤ß·P¬V±±¨î³B¥D¥ô¯Îºû¶¯Âå¥Íªí¥Ü¡A¶}©l¦³±wªÌ¥X²{¦h­«§ÜÃĩʡA±¡ªp¥O¤H¾á¼~

½Ã¥Í¨¾Å@¤¤¤ß¤µ¦~±µÀò18©vCA-MRSA§e³ø­Ó®×¡A¸û¥h¦~¥þ¦~ªº7©v¼W¥[ªñ1.6­¿¡A¨ä¤¤¥»¤ë­º¨â©P¤w±µÀò4©v·s­Ó®×¡C¥Ñ©ó¡u´cµß¡vÄݦÛÄ@§e³ø¶Ç¬V¯f¡A¦³Ãö­Ó®×¼Æ¥Ø¨Ã¥¼¤Ï¬M²{¹ê·P¬V±¡úG¡A¾Ú­»´ä¤j¾Ç·P¬V¤Î¶Ç¬V¯f¤¤¤ß¸ê®ÆÅã¥Ü¡A¤µ¦~­º10­Ó¤ëªº²Ö¿n­Ó®×¤w°ª¹F26©v¡A¯f¬r§ó¥X²{5­Ó·sÅܺØ

¯Îºû¶¯±µ¨ü³X°Ý®É«ü¥X¡A¦bÂå°|¥X²{ªº§ÜÃĩʪ÷¶À¸²µå²yµß¡A·P¬V²v¶È0.5¢H¦Ü1%¡A¦ýCA-MRSA«h°ª¹F30%¡A¡u§Y¨Ï¥Ö½§¥u¦³¤p¶Ë¤f¡A¯fµß¤]¥i³y¦¨ÄY­«·P¬V¡A¦~¬ö¤j¡BºC©Ê¯f±wªÌ¸û©ö·P¬V¡A¦ý°·±dªº¦~»´¤H¥ç¨S¦³¨Ò¥~¡v

CA-MRSA§e³ø­Ó®×¤µ¦~¤j´T¼W¥[¡A¦ý¯Îºû¶¯±j½Õ¡u¥»´ä¥¼¥X²{¤j³W¼ÒÃzµo¡v¡A¦]¬°¡u¥Ø«e©Ò±µÀòªº¡A§¡¬O­Ó§O­Ó®×¡A¥¼¦³²Õ¸sÃzµo¡AÁö¦³­Ó®×¬O¸g¥Ñ®a®x¦¨­û¶Ç¬V¡A¦ý¬Ý¤£¥X¬O°ª¦M¸s¡v

¥LÄòºÙ¡A¥Ø«e¤K¦¨CA-MRSA­Ó®×ÄÝ»´·L·P¬V¡A¦p¥Ö½§µoª¢¡B¥ÍÁw½Hµ¥¡A¦ý¤£¯à»´µø¡A¦]¡u´cµß¡v¥iÄÀ©ñ¬r¯À¡A¯}Ãa¥Õ¦å²y¡A´î§C¤HÅé©è§Ü²Óµß¯à¤O¡A¤@¥¹¬r¯À¤J¦å¡A¥i¤Þ°_¸£½¤ª¢¡BÃa¦º©ÊªÍª¢¡A¦º¤`²v°ª¹F¤­¦¨¡A¡u¯fµß³y¦¨ªº¯}Ãa«Ü§Ö¡A¯f¤H¥i¥H¦b¼Æ¤Ñ¤º¦º¤`¡v¡C¥h¦~«K¦³¤@¦W¤k¤l·P¬V¸Óµß«á¦º¤`

CA-MRSA±wªÌ¹ï½L¥§¦èªL¡B«C¾`¯À©MÀYÌUµß¯Àµ¥¤@½u§Ü¥Í¯À§e§ÜÃĩʡA¤@¯ë»Ý¥ÎÃĤO¸û±jªº§Ü¥Í¯ÀªvÀø¡A¨Ò¦p¦h¦èÀô¯À¡]doxycycline¡^¡B¦Ì¿ÕÀô¯À¡]minocycline¡^¤Î§JªL¾`¯À¡]Clindamycin¡^µ¥¡A¦ý·í¯f¬r¡u·U¨Ó·U´c¡v®É¡A³o¨ÇÃÄÀH®É¡uµL®Ä¡v¡C¯Îºû¶¯¥ç³zÅS¡A¥»´ä¦³¤@¦Ü¨â©v­Ó®×ªº±wªÌ¥X²{¦h­«§ÜÃĩʡA±¡ªp¥O¤H¾á¼~

CA-MRSA±aµßªÌ¤@­Ó¼QÀ¡¤]¥i±N´cµß¶Ç¤H¡A¯f¬r§ó¥i¨ÌªþÀô¹Ò¼Æ¤Ñ¡C¯Îºû¶¯ªí¥Ü¡A½ñ¤J¬î©u¡A¥Ö½§¦]°®Àê¦ÓÃzµõ¡A¼W¥[¯fµß·P¬V¾÷·|¡A¥«¥ÁÀ³ª`·N­Ó¤H½Ã¥Í¡A¨Ã§´µ½³B²z¶Ë¤f¡A¤×¨ä²M¼ä¤u¤H¡B«Ø¿v¤u¤H¤Î³½³cµ¥°ª¦M¤H¤h¡AÀ³¸g±`±a¤â®M¡A¥H¨¾¨ü·P¬V¡C½Ã¥Í¸pµy«á¥ç·|¨ì¥þ´ä©Ò¦³Åé¨|³õ©Ò¡A¥H¤Î«Ø³y·~°Ó·|¥[±j«Å¶Ç¤u§@

ªñ¦~¥»´äªºCA-MRSA·P¬V­Ó®×©úÅã¼W¦h¡A¶Ç¬V¯f±M®a¤@ª½¾á¤ß¡u´cµß¡v¦­¤w¦bªÀ°Ï¼çÂáAÀH®É¤@µo¤£¥i¦¬¬B¡C½Ã¥Í¨¾Å@¤¤¤ß·P¬V±±¨î³B¥D¥ô¯Îºû¶¯Âå¥Íªí¥Ü¡A¥¿¿n·¥¬ã¨s§â¡u´cµß¡v¦C¤Jªk©w§e³ø¶Ç¬V¯f¡A³Ì§Ö©ú¦~ªì¸¨¹ê¡C¥t¸p¤è¥ç­p¹º±Nªñ¦~¬y¦æªºO-157¤j¸z±ìµß¤Î´³¯l¶Ë´H¦C¤Jªk©w§e³ø¶Ç¬V¯f¤¤¡A¥H¶i¦æ§óºò±KºÊ¹î

¯Îºû¶¯¸ÑÄÀ¡A¿ð¿ð¥¼±NMRSA¦C¤Jªk©w§e³ø¶Ç¬V¯f¡A¥u¦]¬É©w§e³ø©w¸q»Ý­n¤@¬qªø®É¶¡¡A¡u²{®É¦n¦hÂåÅ@¤H­û¤£»{ÃÑMRSA¡A¤@©w­n¦³²M´·©w¸q¤~¥i±À¦æ¡A©Ò¥H³Ì§Ö¥i±æ©ú¦~ªì¡]¸¨¹ê¡^¡v

¦b¸¨¹ê·s«ü¤Þ«e¡A¨¾Å@¤¤¤ß¤wÂX¤jºÊ´úºôµ¸¡A©ó¥»¤ë¥h«H³qª¾¨p®aÂå¥Í©M«æ¯g«Ç¡A­Yµo²{¯f¤H¦³¤£´M±`¶Ë¤f·P¬V¡A¨Ò¦p¶Ë¤f«ùÄò¬yÁw¤£Â¡µ¥¡A¥i§â¼Ë¥»°e¨ì¬F©²¤ÆÅç«Ç§K¶O¤ÆÅç¡C¥t¥~¡A¥¼½T©w±wªÌ®a¤H¬O§_¦P¼Ë±aµß«e¡AÂåÅ@¤H­û·|¥ý¬£µoÃÄ»I¤©¥L­Ì¡A§h©J¥L­Ì¦b¦Ü¤Ö5¤Ñ¡A¦b»óµÄ¶î¤WÃÄ»I¡A¥H¨¾±N¯f¬r¶Ç¬V¥L¤H

¶Ç¬V¯f±M¬ìÂå¥Í«ü¥X¡A§Y¨Ï¶Ë¤f¬Æ¬°²Ó¤p¡A¦pÀ½À£­±¤Wªº·t½H¡A­Y¤â«ü¬V¦³§ÜÃĩʪ÷¶À¸²µå²yµß¡A³z¹L·t½H¶Ë¤f¶i¤J¥Ö¤U²Õ´µoª¢¡A¤]¥i¥O¨­Åé·P¬VCA-MRSA

½Ã¥Í¸p³Ì·s±µÀòªº·P¬VCA-MRSA¦º¤`­Ó®×¡A±wªÌªì®É¥uµo²{­±³¡¦³¸~µh¡A¦ý«o¦bµo¯f«á5¤é¦º¤`¡C¶Ç¬V¯f±M¬ìÂå¥Í³Ò¥Ã¼Ö¸ÑÄÀ¡A¥Ñ©óCA-MRSA¥i»s³y¬r¯À¡A¯}Ãa¨­Åé´`Àô¨t²Î¡B¤ßŦ¡BµÇŦµ¥¾¹©x¡A¥O¦åÀ£«æ³t¤U­°¡A¥X²{¤¤¬r©Ê¥ð§J¼xª¬¡A­Y¥¼Àò¤Î®É·m±Ï¡A¥i¦b24¦Ü48¤p®É¤º¦º¤`¡A¦º¤`²v°ª¹F¤­¦¨

¬°¥[±j°»´ú¤Î¶EÂ_CA-MRSA¡AÂåºÞ§½ÁÒ¤Uªº«æ¶E«Ç¡A11¤ë°_¥ç¤w®i¶}¤@¶µ°w¹ï©ÊªººÊ¹î­p¹º



¯u¹êªºCase ¤ÀÃþ: ¤À¨É

¦³¦ì¤Ö¤k¦] RLQ Pain¥h¤FAED~­t³dªº¨º¦ìMO dx¬Oectopic pregnancy~µ²ªG­ì¨Ó¬O...rupture appendicitis  P.S¤Ö¤k®Ú¥»¨S¦³pregnancy

Oncologyªº®Ñ¦n¶Q~²Ó²Ó¥»³£­n¹L¤d¤¸



2006 ¦~ 12 ¤ë 14 ¤é  ¬P´Á¥|   ´¸¤Ñ


Cancerous Patients ¤ÀÃþ: Âå¾Ç¥æ¬y

Àù¯g¯f¤H(Stage 4/4S)©Ò©Ó¨ü¨­Åé¤Wªºµh­W~¬O¨ä¥L¤H¨Sªk²z¸Ñªº~complications ©Ò¤Þ­Pªº¯kµh~ chemotherapy,radiotherapy °Æ§@¥Î³y¦¨ªº¤£¾A~¥O¤£¤ÖÀù¯g¯f¤H·Q¦b¨S¦³µh­W¤Uµ²§ô¥Í©R~¦³®Échemotherapy ©M radiotherapy ©µªø¯f¤H¥Í©Rªº¦P®É~¤]©µªø¤F¥L­Ì©Ó¨üµh­Wªº®É¶¡~ Stage 4/4S ªºÀù¯g¤w¸gµLªk¹ý©³®Úªv~³o¼Ë¤l©µªø¥Í©R¬O§_¦³·N¸q¡H



Àù¯gªº§Î¦¨ ¤ÀÃþ: °·±d¥Í¬¡

¦Û¥Ñ°ò§ðÀ»²Ó­M®É , ­º·í¨ä½Äªº´N¬O²Ó­M¥Íª«½¤ªº³Ì¥~¼h , ¤]´N¬O¥Ñ " ²Ó­M½¤ " ¶}©l , ²Ó­M½¤³Q®ñ¤Æ¯}Ãa¤§«á·|²£¥Í§ó¦hªº¯×©Ê¦Û¥Ñ°ò ( L.P.O. ) , ¥¦­Ì¥i¥H³sÂê©Êªº§ðÀ»¾Fªñ¥¿±`ªº²Ó­M¸s , µM«á¥i¥HÄ~Äò©¹¤º§ó²`¤J«I®`¨ì¦Û¤v²Ó­M½è¤¤ªº²É¸¢Å齤 , ¬Æ¦Ü¤¤¤ß¦ì¸mªº²Ó­M®Ö½¤ , ³oºØ¯}Ãa¹Lµ{¨Ï²Ó­M²£¥Í¨âºØ±¡ªp ,  ¤@¬O²Ó­MÄY­«¨ü·l¦Ó¦º¤` , ¤G¬O¿E¬¡¤F²Ó­M®Ö¤¤ªº " ­PÀù°ò¦] " ( Oncogens ) , ­PÀù°ò¦]¶}©l§ïÅÜ¥¿±` DNA ªºµ²ºc , ¦Ó«á³vº¥µo®i¥XÀù«e²Ó­M , ³Ì«á¦æ¦¨¯u¥¿ªº¸~½F²Ó­M . ©Ò¦³ªº¥Íª«½¤³£¬O§tÁCªº¯×ªÕ½¤¼h , ¦Û¥Ñ°ò¬¡©Ê®ñ«I¤J¯×ªÕ½¤¶i¦æªº´N¬O®ñ¤Æ§@¥Î (Oxidation ) , ¦h¤¸¤£¹¡©M¯×ªÕ»Ä©Ò²Õ¦Xªº¥Íª«½¤³Q®ñ¤Æªºµ²ªG·|²£¥Í§ó±jªº¯×©Ê¹L®ñ¤Æª« ( L.P.O. ) , ³sÄò´c¤Æ´`Àô¨ÑÀ»

«Ü¦h¤£¦P¨Ó·½ªº¦Û¥Ñ°ò , ÀHµÛ¦å²G´å¨«©ó²Õ´²Ó­M¶¡ , ¦ø¾÷¦Ó§ðÀ» , °I°h«¬ªº²Ó­M³Ì©ö¾D¦Û¥Ñ°ò¶Ë®`. ¤H¦³¥Í , ¦Ñ , ¯f , ¦º , ²Ó­M¤]¦³¥|¬ÛªºÅÜ¤Æ , ´N¬O°·±d«¬²Ó­M , ¾÷¯à¤£¨¬«¬²Ó­M , ¨ü¶Ë«¬²Ó­M¥H¤Î°I¦Ñ«¬²Ó­M . ¨ä¤¤¥H¾÷¯à¤£¨¬«¬°I°hªº²Ó­M³Ì®e©ö¨ü¨ì«I®` , ³oÃþ«¬ªº²Ó­M¥»¨­§K¬Ì¨¾¿mªº¥\¯à³£¤w­°§C , ³q±`¦¨¬°Àù²Ó­M¦nµoªº¹ï¶H , ¤H¤@¯ë³£¤¤¦~¥H«á¶}©l°I°h , ®Ú¾Úªñ¦~¨ÓÀù¯g¦º¤`¤H¤f¦~ÄÖªº²Î­pÅã¥Ü , ¦~ÄÖ 45 ·³¥H¤W¨ä¦º¤`¤H¼ÆÀH¦~ÄÖ¼Wªø¦Ó¼W¥[ , ¨ì 60 ~ 64 ·³®É¬°³Ì°ªÂI , µM«á¦A½wºCªº»¼´î . 

¦ý¤HÅé¦]¹L¥÷³Ò²Ö , ºÎ¯v¤£¨¬ , ©Î¬O¤é±`¶¼­¹¦³¯Ê¥¢¥H¤Î¥~¦bÀô¹Ò«~½è§C¦H¦pªÅ®ð , ¤ô½è ......µ¥ ; ³£·|³y¦¨¤HÅé²Ó­M¾÷¯à°I°h , ¦ÓÅý­PÀù°ò¦]­¼µê¦Óµo

Àù¯gªºµo¥Í¤£½×¬O¿ò¶Ç¦]¯À©Î¬OÀô¹Ò¦]¤l , ¨Ò¦p¯f¬r , ¿ç®g½u , ¤Æ¾Çª«½è , ¤]¤£ºÞ¤º¦b¦]¤l©Î¥~¦b¦]¤l , °l®Ú´N©³³£©M°ò¦]¦³Ãö , ¦³¤H»{¬°­PÀù°ò¦]¬O¾É­PÀùÅܪºÁ`¼Ï¯Ã , ¤HÅ骺°ò¦]®w¦X­p¦³¤T¤Q»õºØ°ò¦] , ¦ý¨C¤@ºØ¸~½F§Î¦¨ªº­PÀù°ò¦]³q±`¥u¬O 1 ~ 2 ºØ , ³Ìªñ¤Sµo²{¥X¤@ºØ©M­PÀù°ò¦]¬Û§Ü¿Åªºªº " §íÀù°ò¦] " , ¶·²Å¦X¦ÛµM¬Û§Ü¿Åªº­ì²z , ¥¿±`²Ó­M¤¤ªº²Ó­M®Ö¤]¦³ " §íÀù°ò¦] "ªº³]¸m , ¥­±`¥i¥H¨î¿Å " ­PÀù°ò¦] " µo´§­PÀùªº§@¥Î , ¦ý¦pªG¬Y¨Ç¤º¥~¦]¯ÀÅý­PÀù°ò¦]©ô²±³Q¿E¬¡°_¨Ó , §íÀù°ò¦]¤SµL¤O¤Ï¨î®É , ¨ºÀù¯gªº¦¨§Î´N¶ÕÃøÁ×§K¤F



2006 ¦~ 12 ¤ë 13 ¤é  ¬P´Á¤T   «B¤Ñ


¦å®×²{³õ ¤ÀÃþ: ¤À¨É

¦³¦ì hemorrhoids ªºpt·Ócolonoscopy«efleet enema~¥L¦btoilet¤¤½ñ¤W´ZªO~§Ë±o´Z®æ¥|©P³£¬O¦å~µM«á­YµL¨ä¨ÆÂ÷¶}~¦³¦ìHCA¨£¨ì«á¥H¬°µo¥Í¦å®×~¥h¤FAED call police~±¡ªp¤@«×ºò±i~ÂZÄc¤@°}¤~¯u¬Û¤j¥Õ~µêÅå¤@³õ



2006 ¦~ 12 ¤ë 11 ¤é  ¬P´Á¤@   ´¸¤Ñ


²O¤Ú¸¢¸~¤jªº¨k¥K ¤ÀÃþ: Âå¾Ç¥æ¬y

¤@¦ì29·³¨k¥KÀV³¡¥k¤U¤è²O¤Ú¦ì¸m¥X²{¤F1.5cmx1.35cmªºmass~cannot be resolved by antibiotics~¨ä¥L¥D­n¼xª¬: PSVT,Palpitation ~~¸g¹LÁ{§É¶EÂ_~´c©Ê¸~½Fªº¾÷·|²v¬O1%~­Y­nªÖ©w¬O§_´c©Ê¸~½F~»Ý©â¥XÀV³¡²O¤Ú²Õ´§@¶i¤@¨B¤ÆÅç~(¨ä¹ê¦pªG©È¥´°w©â²Õ´~¥i¥H°µCT Neck ©Î USG ³£¥i¥HÅç¨ì~¤£¹L¦n¹³¤pÃD¤j°µ)

P.S ­Y¬O Gastrointestinal Carcinoma metastasis via lymph node,·|¤Þ­P¥ªÂê°©¤W¤è²O¤Ú¸~¤j~~­Y¬O NPC metastasis via lymph node,«h·|¤Þ­PÀV¤W¤è²O¤Ú¸~¤j~~¦¹¥~,ÁÙ­n¬Ý½Fªºsize¦³§_¼W¤j¤Î¨äµo®i±¡ªp



Call¾÷ÅT¤£°± ¤ÀÃþ: ¤u§@¤é°O

½Õ¤F¥h·sdepartment«á~call¾÷ÅTªº¦¸¼Æ©úÅã¦h¤F~·Q¤£¨ìsecond callªºcall¾÷³£·|¤£°±¦aÅT

¼g§¹¤F²Ä8¥÷paper~¤£¹L¬Û¤ñ°_QMH MD GID SMO ªºC¤p©j~¦o¤J¦æ13¦~¦@¼g¤F¶W¹L100¥÷paper~¬Ý¨Ó§Ú¤´»Ý§V¤O...

SOPD Waiting List:1st preference~within 2 weeks 2nd preference~within 8 weeks No preference~32 to 88 weeks

OT Waiting List:Emergency~10 days Non-emergency~12 to 35 weeks



2006 ¦~ 12 ¤ë 10 ¤é  ¬P´Á¤é   ´¸¤Ñ


¨«¶iÀù¯gªº¥@¬É ¤ÀÃþ: °·±d¥Í¬¡

Àù¯g¬O²Ó­M¤£¥¿±`ªº¤Àµõ~¦³¨Ç¦¨¦]¨ÌµM¤£©ú~¤j¦h¼ÆÀù¯gªì´Á¨S¦³©úÅã¼xª¬~¦]¦¹¦³³¡¥÷¤H¨D¶E®É¤w¬O¥½´ÁÀù¯g~~¥HÀù¯gªº¶¥¬q¨Ó¤À~½ñ¤J¤FStage 2A ªºÀù¯g¤w¸g¤£¥i¥H¥Î¥~¬ì¤â³N¹ý©³²M°£Àù²Ó­M

¥H­¹¹DÀù(oesophagus carcinoma)¬°¨Ò~¦­´Áµo²{±w¤W­¹¹DÀùªº¯f¤H5¦~¦s¬¡²v¥i¹F80~90%~¥½´Á¤~µo²{ªº¯f¤H5¦~¦s¬¡²v¤£¨¬10%~~¥Ñ©ó¦~»´¤Hªº·s³¯¥NÁ¸û§Ö~©Ò¥H¦~»´±wªÌªºÀù²Ó­MÂX´²³t«×¤ñ¦~ªø±wªÌ¬°§Ö~~¤£¦PºØÃþªºÀù¯g¤]·|¦³¤£¦PªºÂX´²³t«×~¨ä¤¤¥HHCC©MSCLCÂX´²¤ñ¸û¨³³t~SCLC±wªÌªº5¦~¦s¬¡²v¤Ö©ó20%

¸~½F¾Ç±M®a¤w¦³¦@ÃÑ~Àù¯g¬O¥þ¨­©Ê¯e¯f~~ÁöµM³¡¥÷Àù¯g¦¨¦]¤£©ú~¦ý¥i¥H¦b¤wª¾ªº¦¨¦]¤¤§@¥X¹w¨¾~´î§C±w¤WÀù¯gªº¾÷·|

 



C¥ý¥Í ¤ÀÃþ: ¤À¨É

¦Û±qC¥ý¥Í¨Órotate«á~¦h¤F¤£¤Ö½ì¨Æ~¨ä¥L¤H¥¿¦£µÛCPR,¥´¤jAªº¦P®É~¥L¯¸¦b­I«á¦YªF¦è~~³¨³½¥¢±Ñ~~false Dx~~¥´IV¤£¤¤target~~AÅÜV~~ÁÙ¦³...

C¥ý¥Í1¤ë­n¦Òpart2~¥H¥L²{¦bªºstandard......

P.S C¥ý¥Í»¡¥Lªº¥Ø¼Ð¬O¥[¤JPYNEH Clinical Oncology or Neurosurgery ©Î QMH AED...¦³¥Ø¼Ð²¦³º¬O¤@¥ó¦n¨Æ



¨C¤ë¸g±`©Ê¶}¤ä ¤ÀÃþ: §Úªº¥Í¬¡

¶}¤ä...............................¦û¤ëÁ~¦Ê¤À¤ñ
¨Ñ¼Ó(¨ª¬W)(30¦~/¤C¦¨«ö´¦).......72%
ºÞ²z¶O(¨ª¬W)..........................3%
ºÞ²z¶O(LCK)...........................0.4%
Âø¶O(¹q¶O.¤ô¶O.·Ñ®ð¶O.etc).........0.7%
®½´Ú(¤º¦a§U¾Ç¨àµ£.µL°ê¬ÉÂå¥Í)....10%
µ¹®a¤H®a¥Î..............................10%